Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Janux Therapeutics, Inc.NASDAQ: JANX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $11.13M rose 13.1% year over year, ahead of the -1.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.

Context

  • Selling, general & admin amounted to 417.7% of revenue in FY2025, up 30.0 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 11 analysts of $93.52M (+123.9%) for the fiscal year ending Dec 2026, a step up from the +1.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.13M+2.6% QoQ
Last fiscal yearDec 2025
$41.77M+1.8% YoY
LTMMar 2026
$42.56M-1.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.1%+509.9%+496.8 pp
1 year+1.8%+123.9%+122.1 pp
3-year CAGR+23.3%-16.7%-40.0 pp
5-year CAGR+54.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
41.77M USD
Year-over-year change
+1.8%
4-year CAGR
+41.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.1% is the 7th highest of 10, against a peer median of +10.2%.
  • Selling, general & admin amounts to 196.9% of revenue for JANX, versus a peer median of 61.5%.
JANX Competitors
Selling, General & Admin for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
IMNMImmunome, Inc.LTM Sep 2026$64.15M USD+52.3%+47.5%—
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$52.28M USD-5.2%+10.5%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$51.3M USD+21.7%+17.2%45802.7%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.56M USD-1.1%+23.3%196.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M USD-27.9%-11.7%35.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$31.1M USD-1.0%-11.4%87.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M USD+10.2%+13.1%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —+10.2%+12.3%61.5%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.